CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Reneo Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Reneo Pharmaceuticals Inc
18575 Jamboree Road, Suite 275-S
Phone: (858) 283-0280p:858 283-0280 IRVINE, CA  92612  United States Ticker: RPHMRPHM
Business Summary
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board MichaelGrey 70 12/1/2017 9/1/2014
President, Chief Executive Officer, Director Gregory J.Flesher 52 11/1/2020 1/1/2019
Co-Founder, Director NiallO'Donnell 50 11/1/2020 12/1/2017
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
RENEO PHARMA LTD Innovation House Office 13, Second Floor Discovery Park Kent United Kingdom

Business Names
Business Name
Reneo Pharma Ltd
RPHM

General Information
Number of Employees: 8 (As of 12/31/2023)
Outstanding Shares: 33,420,808 (As of 3/26/2024)
Shareholders: 184
Stock Exchange: NASD
Federal Tax Id: 472309515
Fax Number: (302) 674-5266


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024